BioSpace News Archive

- Data further demonstrate proof-of-concept for the therapeutic potential of apitegromab in patients with Type 2 and Type 3 SMA - Phase 3 registrational trial initiation expected by the end of 2021 - European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to apitegromab, recognizing unmet medical needs of patients with SMA

Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 8:45 a.m. ET.

Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema’s Scientific Advisory Board

Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on recent FDA feedback and ongoing interactions Clinical expansion efforts underway for elamipretide in rare metabolic cardiomyopathies and in rare mitochondrial disease caused by nuclear DNA mutations

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2021 after the close of trading on Tuesday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 10:15 a.m. ET.

Augmedix, Inc. (OTCQX: AUGX), a leading provider of remote medical documentation and live clinical support, today announced the company will be participating in the upcoming 20th Annual Needham Virtual Healthcare Conference. Augmedix’s management is scheduled to present on Thursday, April 15, 2021 at 1:30 p.m. Eastern Time.

Valo Health LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry , Ph.D., founder and Chief Executive Officer of Valo will present at the BMO BioPharma Spotlight